Silybin B and Cianidanol Inhibit M pro and Spike Protein of SARS-CoV-2: Evidence from in Silico Molecular Docking Studies.

CONCLUSION: Silybin B and Cianidanol showed excellent binding and ADME properties compared with the currently endeavored drugs and can be exploited as therapeutic options against SARS-CoV-2 infection after experimental validation and clinical trials. PMID: 33302853 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33302853?dopt=Abstract

Source: Current Pharmaceutical Design - December 10, 2020 Category: Drugs & Pharmacology Authors: Srivastava R, Tripathi S, Unni S, Hussain A, Haque S, Dasgupta N, Singh V, Mishra BN Tags: Curr Pharm Des Source Type: research